MEG3 and metabolic dysfunction-associated steatotic liver disease: Combining in vitro and in vivo NAFLD models, as well as clinical NAFLD samples, we presented evidence that MEG3 downregulation is not only a biomarker for NAFLD, but a critical regulator for lipid metabolism and inflammation.